Evidence snapshot
A synthetic cyclic melanocortin agonist. It can affect pigmentation and other physiological responses because it is not limited to a single melanocortin receptor.
Why it stands out
Its research appeal is a visible biological effect linked to a defined signaling system. Beyond pigmentation, early work explored sexual responses, helping researchers understand why one peptide can influence different functions.
How it may work
It activates multiple melanocortin receptors involved in pigment production, appetite, and sexual response.
What studies found
A small phase 1 study reported increased pigmentation in human volunteers. Separate early studies documented erectile responses. These establish biological activity, but were not large, long-term trials of a safe cosmetic tanning product.
What the evidence means
A visible tan is a measurable effect, not evidence of protection from ultraviolet damage. The small human studies cannot establish long-term skin outcomes or the safety of repeated cosmetic use, and the molecule remains unapproved by the FDA.
Safety and limitations
Nausea, flushing, spontaneous erections and changes in freckles or moles have been reported. New or changing pigmented lesions need assessment. Melanotan does not replace sunscreen, and a prolonged erection requires urgent medical attention.
Current status
Melanotan II is not FDA-approved.
Common questions
Is Melanotan II the same as approved afamelanotide? No. Related melanocortin compounds have different selectivity, formulations and clinical evidence. Approval of another molecule does not transfer to Melanotan II.
Personal accounts, not clinical results
A long-term user in the linked discussion describes greater satisfaction with their skin tone and less reliance on self-tanner, while also mentioning new moles. That is a personal cosmetic experience, not evidence that pigmentation changes are harmless or protective.